A detailed history of Bank Of New York Mellon Corp transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Bank Of New York Mellon Corp holds 131,398 shares of FDMT stock, worth $2.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
131,398
Previous 144,940 9.34%
Holding current value
$2.7 Million
Previous $2.94 Billion 42.56%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 25, 2024

SELL
$17.03 - $35.87 $230,620 - $485,751
-13,542 Reduced 9.34%
131,398 $4.19 Billion
Q4 2023

Jan 29, 2024

BUY
$9.76 - $21.25 $90,075 - $196,116
9,229 Added 6.8%
144,940 $2.94 Billion
Q3 2023

Oct 24, 2023

BUY
$12.64 - $19.76 $245,645 - $384,015
19,434 Added 16.71%
135,711 $1.73 Billion
Q2 2023

Aug 03, 2023

BUY
$15.16 - $23.26 $118,581 - $181,939
7,822 Added 7.21%
116,277 $2.1 Billion
Q1 2023

May 09, 2023

BUY
$15.45 - $23.19 $1.68 Million - $2.52 Million
108,455 New
108,455 $1.86 Billion
Q4 2022

Feb 14, 2023

BUY
$6.85 - $25.46 $752,883 - $2.8 Million
109,910 New
109,910 $2.44 Million
Q3 2022

Nov 14, 2022

BUY
$6.96 - $11.48 $65,493 - $108,026
9,410 Added 9.62%
107,217 $862,000
Q2 2022

Aug 15, 2022

SELL
$5.68 - $15.99 $19,965 - $56,204
-3,515 Reduced 3.47%
97,807 $682,000
Q1 2022

May 11, 2022

BUY
$13.16 - $22.64 $14,949 - $25,719
1,136 Added 1.13%
101,322 $1.53 Million
Q4 2021

Feb 11, 2022

BUY
$19.56 - $32.94 $605,734 - $1.02 Million
30,968 Added 44.74%
100,186 $2.2 Million
Q3 2021

Nov 12, 2021

BUY
$22.73 - $36.04 $922,428 - $1.46 Million
40,582 Added 141.72%
69,218 $1.87 Million
Q2 2021

Aug 11, 2021

BUY
$22.2 - $42.29 $182,461 - $347,581
8,219 Added 40.26%
28,636 $689,000
Q1 2021

May 13, 2021

BUY
$35.94 - $52.67 $733,786 - $1.08 Million
20,417 New
20,417 $885,000

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $666M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.